Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|July 22, 2021

Paving a Path Forward to Overcome Stigma

Author(s)Shahla Modir, MD

A recent All Points North Lodge survey found 37% of Americans are comfortable discussing mental health, but 44.7% have never tried counseling. What is preventing them from seeking care?

Despite the difficult past 2 years, negative views of mental health persist. Shahla Modir, MD, discusses the results of the All Points North Lodge survey and gives reccomendations to improve mental well-being.

To see more from this survey, check out COVID-19 Blues.

Dr Modir is the Chief Medical Officer at All Points North Lodge and the Chief Psychiatrist at Avalon Malibu, Summit Malibu.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

chatbot

Preliminary Report on Dangers of AI Chatbots

ByAllen Frances, MD,Luciana Ramos

October 7th 2025

Socrates

“By His Own Hand”: Socrates’ Suicide as an Affirmative Choice, A Reply to Rev. Christopher Dreisbach, PhD

ByVincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

October 1st 2025

Artificial Intelligence Will Never Replace Psychiatry—But It Will Try to Destroy It

ByDaniel Morehead, MD

September 18th 2025

brain shooting

No, Antidepressants Do Not Provoke Mass Shootings

ByJames L. Knoll IV, MD,Ronald W. Pies, MD

September 12th 2025

ketamine

Access to Care: The Case of Ketamine

ByLisa Harding, MD

September 11th 2025

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

The Social Challenge of the Powerful Taking Care of the Poor: Columbus Day, Indigenous People’s Day, and More

Early Dose Management and Up-Titration of Esketamine: ECNP Poster Data

Asynchronous ADHD Assessment: New Tools for Better Evaluation

Women Are Diagnosed With ADHD 5 Years Later Than Men

Seltorexant Well-Tolerated in Adolescents as an Adjunct Treatment for Major Depressive Disorder

© 2025 MJH Life Sciences^®

All rights reserved.